7 completed, 6 recruiting, 3 terminated, 1 enrolling by invitation. 20 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 7, Recruiting 6, Terminated 3, Enrolling by invitation 1, Not yet recruiting 1, Suspended 1, Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow belumosudil: new trials by email Literature Review of belumosudil trials Research Report on belumosudil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD) Belumosudil, Ruxolitinib - cGVHD | Phase 2 | Not yet recruiting | Dennis Kim | 53 | 2026-11-01 | 2026-10-02 |
| A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) Belumosudil - Chronic Graft Versus Host Disease | Phase 2 | Recruiting | Sanofi | 37 | 2025-12-02 | 2026-09-22 |
| Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation Belumosudil 200 mg QD, Placebo - Rejection Chronic Renal | Phase 2 | Enrolling by invitation | The Methodist Hospital Research Institute | 40 | 2025-09-11 | 2025-11-12 |
| Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy Belumosudil - Chronic Graft Versus Host Disease | Phase 2 | Withdrawn | Kadmon, a Sanofi Company | 2025-06-16 | 2026-02-12 | |
| A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant Belumosudil - Graft Versus Host Disease, Graft Vs Host Disease | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 46 | 2025-05-21 | 2026-06-29 |
| Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients Belumosudil, Placebo for Belumosudil - Lung Transplant | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 234 | 2025-03-12 | 2026-08-10 |
| BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) Belumosudil, Fluticasone, Azithromycin - Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 45 | 2024-05-31 | 2026-06-10 |
| Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease Belumosudil, Rituximab - Chronic Graft Versus Host Disease | Phase 2 | Suspended | Northside Hospital, Inc. | 25 | 2024-01-29 | 2026-10-16 |
| Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease Belumosudil, Biospecimen Collection, Electronic Health Record Review - Chronic Graft Versus Host Disease | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 82 | 2023-12-06 | 2026-09-17 |
| Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213 Belumosudil 200 mg QD, Belumosudil 200 mg BID, Belumosudil 400 mg QD - Chronic Graft-versus-host-disease | Phase 2 | Completed | Kadmon, a Sanofi Company | 23 | 2022-02-23 | 2025-05-02 |
| Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD) BN101 - GVHD, Chronic | Phase 2 | Completed | BioNova Pharmaceuticals (Shanghai) LTD. | 30 | 2021-04-27 | 2024-01-17 |
| Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis Belumosudil - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Terminated | Kadmon, a Sanofi Company | 10 | 2021-03-03 | 2023-06-05 |
| Isatuximab in Combination With Novel Agents in RRMM - Master Protocol Isatuximab, Dexamethasone, Pomalidomide - Plasma Cell Myeloma Refractory | Phase 1 / Phase 2 | Recruiting | Sanofi | 258 | 2021-01-25 | 2026-10-13 |
| KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis Belumosudil (KD025), Placebo - System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Terminated | Kadmon, a Sanofi Company | 36 | 2019-06-26 | 2023-08-30 |
| Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy Belumosudil (KD025) - Chronic Graft-versus-host-disease | Phase 2 | Terminated | Kadmon, a Sanofi Company | 159 | 2018-10-11 | 2024-12-12 |
| A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease Belumosudil (KD025) - Graft vs Host Disease | Phase 2 | Completed | Kadmon, a Sanofi Company | 54 | 2016-09-15 | 2023-06-28 |
| A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis Belumosudil, Placebo - Chronic Plaque Psoriasis | Phase 2 | Completed | Kadmon Corporation, LLC | 110 | 2016-09-14 | 2022-03-16 |
| A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis Belumosudil, BSC - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Kadmon Corporation, LLC | 76 | 2016-05-26 | 2022-09-08 |
| Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy KD025 - Psoriasis Vulgaris | Phase 2 | Completed | Kadmon Corporation, LLC | 38 | 2014-12-01 | 2022-05-26 |
| A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris Belumosudil - Psoriasis Vulgaris | Phase 2 | Completed | Kadmon Corporation, LLC | 8 | 2014-04-01 | 2022-03-23 |
Bronchiolitis Obliterans Syndrome (8) · Graft vs Host Disease (2) · Lung Diseases (2) · Pulmonary Fibrosis (2) · Scleroderma, Diffuse (2) · Skin Diseases (2) · Acute Lung Injury (1) · Bronchiolitis Obliterans (1) · Fibrosis (1) · Hematologic Neoplasms (1) · Idiopathic Interstitial Pneumonias (1) · Idiopathic Pulmonary Fibrosis (1) · Immune System Diseases (1) · Organizing Pneumonia (1) · Plaque, Amyloid (1)
Kadmon, a Sanofi Company (6) · Kadmon Corporation, LLC (4) · Sanofi (2) · BioNova Pharmaceuticals (Shanghai) LTD. (1) · Dana-Farber Cancer Institute (1) · Dennis Kim (1) · Fred Hutchinson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Northside Hospital, Inc. (1) · The Methodist Hospital Research Institute (1)
United States (17) · Canada (3) · China (2) · France (2) · Germany (2) · Israel (2) · Italy (2) · Australia (1) · Belgium (1) · Greece (1) · Japan (1) · Netherlands (1) · Norway (1) · South Korea (1) · Spain (1)
Corey Cutler, MD, MPH (1) · Depei Wu, Prof (1) · Doris Ponce, MD (1) · Scott M. Palmer, M.D., M.H.S. (1) · Scott Solomon, MD (1) · Stephanie Lee, MD, MPH (1)
PMID 34265047, PMID 35781099, PMID 10387937, PMID 10845940, PMID 10997973, PMID 11222360, PMID 11509929, PMID 11981005, PMID 12070007, PMID 12931119, PMID 14512314, PMID 15142114, PMID 15251978, PMID 15292060, PMID 15613541, PMID 16046530, PMID 16239908, PMID 16551963, PMID 16788100, PMID 16946302, PMID 17549053, PMID 17671231, PMID 19597425, PMID 22500839, PMID 23861248, PMID 24315843, PMID 24820310, PMID 25385601, PMID 25395505, PMID 25687558, PMID 25985915, PMID 2670000, PMID 26983850, PMID 27436361, PMID 29281578, PMID 3042041, PMID 30518977, PMID 33877856, PMID 38532458, PMID 40088930, PMID 40311075, PMID 8485479, PMID 9027268, PMID 9193757